Board

James Wakefield
Non-exec Director & Chairman of the Board

  • James is an experienced private equity investor having spent over 30 years in the industry.
  • His vast experience ranges from chairing a number of successful Board teams, investment committees and being involved with originating/executing new transactions, portfolio management and fundraising.
  • James has been Chairman or Non-Executive Director of over 30 companies of varying sizes/stages of development across a wide range of sectors.

David Allmond
Chief Executive Officer

  • Appointed CEO of Novacyt in 2021
  • Over 25 years of global experience in pharmaceuticals & biopharmaceutical companies
  • Internationally experienced, strategic business leader with strong track record in global commercialisation
  • Built & led multiple diverse, successful teams in dynamic growth companies including Amgen, Celgene & Amryt Pharma
  • C-level executive with AIM and NASDAQ listed companies

James McCarthy
Chief Financial Officer

  • Appointed CFO of Novacyt in 2021
  • Over 30 years in international manufacturing and industrial businesses in both consumer and B2B
  • CFO in both Private Equity and public businesses.
  • FCCA qualified over 30 years with broad commercial, supply chain and M&A experience

Dr Andrew Heath
Non-exec Director

  • Dr Heath is a healthcare and biopharmaceutical executive with in-depth knowledge of US and UK capital markets with international experience in marketing, sales, R&D and business development.
  • He is currently Deputy Chairman and SID of Oxford BioMedica plc.
  • From 1999 to 2008 he was CEO of Protherics plc, taking the company from 30 to 350 staff and managing its eventual acquisition by BTG Plc for £220 million.
  • A former director of The BioIndustry Association, Dr Heath earlier served as Vice President of Marketing and Sales, for Astra Inc. in the US after a career in clinical and academic medicine at Vanderbilt University.

Jean-Pierre Crinelli
Non-exec Director

  • One of the founders of Novacyt in July 2006.
  • 30 years in the car and electrical components industry (various functions/M&A/business restructuring).
  • Of which 10 years Outside France: Singapore, North America, Belgium and Italy.

Juliet Thompson
Non-exec Director

  • Non-executive Vice Chairman of Nexstim, a listed Finnish medical technology company
  • Non-executive Director of Vectura, an industry-leading device and formulation business, based in the US.
  • A 20+ years strong track record advising listed healthcare companies in UK and Europe as an investment banker
  • Managing Director Nomura Code
  • Chartered Accountant and substantial experienced in equity fundraisings and M&A

Dr Edwin Snape
Non-exec Director

  • Over 40 years of experience in founding, investing in and guiding the development of many public and private healthcare and speciality materials companies
  • He is a co-founder of NMT Capital (a successor of Nexus) and continues to work as one of its senior advisers.
  • He is also a senior adviser to Maruho Co., Ltd, a director of SAI Holding Company and a co-owner of Nexus Medical, LLC, the general partner of Nexus Medical Partners II, L.P. Prior to NMT Capital he was managing general partner of The Vista Group, Chairman of Orien Ventures, a private equity firm with Pacific Rim affiliations; and, a director of the Cygnus Funds, two United Kingdom-based private equity firms specializing in investments throughout Europe.
  • He holds a Bachelor of Science and PhD degrees in metallurgy from Leeds University, United Kingdom.